CCR5 and metabolic dysfunction-associated steatohepatitis: Monocytes and T cells express CCR2 and CCR5, so cenicriviroc (CVC) which is a dual CCR2 and CCR5 antagonist can limit their infiltration in the liver and has been shown to limit fibrosis in NASH mice (179–181).